PharmaTimes -
November 2017

Ahead of our Marketer of the Year awards ceremony in November, we thought we’d take a look at some of the most important tools available to modern pharma marketers.

Social media is increasingly important for all industries. Pharma might face an uphill battle to be heard among a sea of celebrities and breaking news -- but as shown in this month’s cover feature (p34), with exclusive research conducted for PharmaTimes, companies are already starting to figure out what works best.

Of course, social media is just one channel among many that marketers can harness to get their message across, and these days marketing is really about multichannel strategies. That said, research shows that the European industry is falling behind in this area, so in The Secrets of Multichannel (p31) we ask how they can start to close the gap.

Other articles this month include a look at an exciting new gene therapy delivery technology (p28), an interview with Bayer’s new UK & Ireland CEO Lars Bruening (p39) and a focus on joint working in IBD Registry Industry Working Group (p20) -- along with a Patient Files focusing on ulcerative colitis (p45).

November 2017 - magazine highlights

Thumbnail image for #pharma

#pharma

An exclusive analysis conducted by Talkwalker for PharmaTimes reveals which companies are the most successful at using social media and what they’re doing right

Thumbnail image for Exposing the true cost of care

Exposing the true cost of care

Sue Thomas and Paul Midgley of Wilmington Healthcare explore how the proposed national patient data sharing scheme would change the NHS

Thumbnail image for Greater good

Greater good

Richard Gardner, British Society of Gastroenterology chief executive, and Jeremy Thorpe, general manager of Tillotts Pharma UK, explain the value of joint working in IBD

Thumbnail image for Delivering the goods

Delivering the goods

Biotech firm Nanogenics believes that its product LipTide could solve one of the oldest problems in gene therapy – delivery. Director of business development Alan Walker and director of pre-clinical development Simon Newman talk to PharmaTimes about their vision for the company and LipTide

Thumbnail image for Age of discovery

Age of discovery

Five years on from Pfizer selling Discovery Park, the site’s current chief executive Toby Hunter tells PharmaTimes about the plans for its future

Thumbnail image for What science really means

What science really means

Five years on from Pfizer selling Discovery Park, the site’s current chief executive Toby Hunter tells PharmaTimes about the plans for its future

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download